Phio Pharmaceuticals Corp...

NASDAQ: PHIO · Real-Time Price · USD
2.21
0.02 (0.91%)
At close: Aug 15, 2025, 3:59 PM
2.12
-4.07%
Pre-market: Aug 18, 2025, 06:42 AM EDT

Phio Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 30K 30K 30K 30K n/a n/a n/a n/a n/a n/a n/a n/a 0.00 0.00 0.00
Cost of Revenue
36K 70K 78K 125K 171K 184K 187K 186K 188K 193K 197K 199K 197K 192K 605K 1.81M 2.54M
Gross Profit
-1K -35K -48K -95K -141K -154K -187K -186K -188K -193K -197K -199K -197K -192K -605K -1.81M -2.54M
Operating Income
-5.18M -7.39M -7.49M -8.68M -9.31M -10.7M -11.66M -12.45M -12.42M -11.46M -12.18M -12.35M -12.51M -13.51M -12.52M -11.09M -10.07M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-6.76M -7.15M -7.42M -8.68M -9.38M -10.83M -11.66M -12.46M -12.44M -11.48M -12.2M -12.37M -12.52M -13.29M -12.3M -10.87M -9.85M
Net Income
-6.76M -7.15M -7.42M -8.68M -9.38M -10.83M -11.53M -12.33M -12.32M -11.36M -12.22M -12.38M -12.52M -13.29M -12.3M -10.87M -9.85M
Selling & General & Admin
3.67M 3.71M 3.74M 3.77M 3.88M 4.32M 4.72M 4.81M 4.86M 4.45M 4.99M 4.86M 4.66M 4.63M 4.25M 4.37M 4.24M
Research & Development
3.38M 3.64M 3.67M 4.83M 5.35M 6.33M 6.94M 7.64M 7.56M 7.01M 7.19M 7.49M 7.85M 8.89M 8.27M 6.72M 5.83M
Other Expenses
n/a n/a 4K n/a -2K -2K -7K -8K -16K -18K -17K -12K -2K n/a n/a -3K -6K
Operating Expenses
7.05M 7.35M 7.41M 8.6M 9.23M 10.65M 11.65M 12.45M 12.42M 11.46M 12.18M 12.35M 12.51M 13.51M 12.52M 11.09M 10.07M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a 5K 15K 17K 18K 16K 9K 9K 8K 5K 2K
Selling & Marketing Expenses
n/a -34K -77K -77K -77K -43K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
5.18M 7.39M 7.49M 8.67M 9.3M 10.7M 11.65M 12.45M 12.42M 11.46M 12.18M 12.35M 12.51M 13.51M 12.52M 11.09M 10.07M
Income Tax Expense
9.28K n/a 41.72K 41.72K 41.72K 56.42K -130.58K -125.58K -115.58K -119K 8K -26K -36K -38K -29K n/a n/a
Shares Outstanding (Basic)
43.07 7.87M 990.03K 510.19K 508.39K 415.95K 270.86K 191.86K 126.78K 126.43K 126.38K 126.34K 125.47K 125.19K 125.19K 125.19K 98.79K
Shares Outstanding (Diluted)
43.07 7.87M 990.03K 510.19K 508.39K 415.95K 270.86K 191.86K 126.78K 126.43K 126.38K 126.34K 125.47K 125.19K 125.19K 125.19K 98.79K
EPS (Basic)
-41.08K -9.77 -13.96 -22.68 -32.35 -56.52 -72.48 -90.55 -97.37 -90.03 -97.08 -98.64 -99.99 -113.41 -131.89 -145.18 -160.12
EPS (Diluted)
-41.08K -9.77 -13.96 -22.68 -32.35 -56.52 -72.48 -90.55 -97.37 -90.03 -97.08 -98.64 -99.99 -113.41 -131.89 -145.18 -160.12
EBITDA
-5.11M -7.28M -7.29M -8.44M -9.1M -10.47M -11.47M -12.27M -12.25M -11.29M -12.03M -12.22M -12.41M -13.44M -12.45M -11.02M -10M
EBIT
-5.18M -7.39M -7.49M -8.67M -9.3M -10.7M -11.65M -12.45M -12.42M -11.46M -12.18M -12.35M -12.51M -13.51M -12.52M -11.09M -10.07M
Depreciation & Amortization
-34K n/a 78K 125K 171K 184K 187K 186K 188K 193K 197K 199K 197K 192K 159K 129K 101K